Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C

被引:91
|
作者
Caballero, T
Pérez-Milena, A
Masseroli, M
O'Valle, F
Salmerón, FJ
Del Moral, RMG
Sánchez-Salgado, G
机构
[1] Univ Granada, Sch Med, Dept Pathol, Granada 18012, Spain
[2] Univ Granada, Univ Hosp, Granada 18012, Spain
[3] Univ Granada, Sch Med, Dept Internal Med, Granada 18012, Spain
关键词
hepatitis C; liver fibrosis; image analysis; automatic quantification; Knodell activity index; Scheuer activity grade; Knodell fibrosis scoring; Scheuer fibrosis staging; interferon;
D O I
10.1016/S0168-8278(01)00006-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The effect of interferon on the reduction of liver fibrosis is controversial. We aimed to compare semiquantitative methods with a quantitative digital image analysis system to assess liver fibrosis in biopsies from patients with chronic hepatitis and different responses to interferon, Methods: We studied 98 liver biopsies with chronic hepatitis C before and after recombinant interferon alfa-2 treatment, using conventional histological assessment, grading of histological activity, scoring/staging of fibrosis (Knodell and Scheuer), and quantification of fibrosis with image analysis (FibroQuant). Results: Sustained-responders to interferon showed a significant reduction in histological lesions and in their Knodell and Scheuer activity indexes. The semiquantitative systems showed no reduction in fibrosis, The FibroQuant application showed a significant reduction in porto-periportal and septal areas among sustained-responders (P < 0.001) and non-responders (P < 0.05), and in porto-periportal and septal fibrosis areas only in sustained-responders (P < 0.001), whereas the percentage of fibrosis increased in non-responders (P < 0.001). Conclusions: The Scheuer system is useful for the daily evaluation of fibrosis, but the FibroQuant application provides more objective data on the anti-fibrogenic effects of interferon, which include a reduction in the portoperiportal area in sustained-responders and non-responders, accompanied by a reduction in the area of fibrosis only when the viral replication has ceased. (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B,V, All rights reserved.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [41] Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
    Cornberg, M
    Hadem, J
    Herrmann, E
    Schuppert, F
    Schmidt, HHJ
    Reiser, M
    Marschal, O
    Steffen, M
    Manns, MP
    Wedemeyer, H
    JOURNAL OF HEPATOLOGY, 2006, 44 (02) : 291 - 301
  • [42] Triple vs. double therapy of chronic hepatitis C infection in non-responder patients with high daily induction dosing of interferon alfa.
    Jaeckel, E
    Koerbel, J
    Kunka, A
    Schueler, A
    Heringlake, S
    Wedemeyer, H
    Trautwein, C
    Zankel, M
    Dreher, A
    Manns, M
    HEPATOLOGY, 1999, 30 (04) : 631A - 631A
  • [43] Which is the most cost-effective combination therapy using interferon alfa-2b plus ribavirin for non-responder patients with chronic hepatitis C?.
    Ricardo, MO
    Carmen, A
    Angel, CM
    Leslie, F
    HEPATOLOGY, 2002, 36 (04) : 577A - 577A
  • [44] Evaluation of initial biochemical and virological responses to induction therapy with interferon-A2B in combination with ribavirin and ketoprofen for non-responder patients with chronic hepatitis C.
    Munoz, AE
    Levi, D
    Miguez, C
    Cisterna, D
    Terg, R
    HEPATOLOGY, 2000, 32 (04) : 554A - 554A
  • [45] Efficacy of interferon-alpha 2b in combination with ribavirin in the treatment of non-responder patients with chronic hepatitis C: A randomised-controlled trial.
    Tassopoulos, NC
    Tsantoulas, D
    Raptopoulou, M
    Paraskevas, E
    Avgerinos, A
    Kanatakis, S
    Vaffiadis, I
    Delladetsima, J
    Demonakou, M
    Sypsa, V
    Hatzakis, A
    HEPATOLOGY, 1999, 30 (04) : 632A - 632A
  • [46] Interest of a higher dose of interferon alpha in non responder patients with chronic hepatitis C: A prospective randomized study.
    Rolachon, A
    Kezachian, G
    Causse, A
    Baud, M
    Fournet, J
    Zarski, JP
    HEPATOLOGY, 1996, 24 (04) : 1770 - 1770
  • [47] Chronic hepatitis C non responder patients to interferon: Results after stopping one year of interferon plus ribavirin combination.
    Diago, M
    Valeros, MD
    Lujan, M
    Cors, R
    Carbonell, P
    Aznar, V
    Andreu, J
    Garcia, V
    HEPATOLOGY, 1998, 28 (04) : 713A - 713A
  • [48] Expression of IFNλ4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients
    Murakawa, Miyako
    Asahina, Yasuhiro
    Nakagawa, Mina
    Sakamoto, Naoya
    Nitta, Sayuri
    Kawai-Kitahata, Fukiko
    Taniguchi, Miki
    Watanabe, Takako
    Itsui, Yasuhiro
    Kakinuma, Sei
    Watanabe, Mamoru
    HEPATOLOGY, 2014, 60 : 1065A - 1065A
  • [49] PREDICTIVE VALUE OF HEPATITIS-C VIRUS DENSITY ANALYSIS FOR RELAPSE IN INTERFERON-TREATED CHRONIC HEPATITIS-C PATIENTS
    KANTO, T
    HAYASHI, N
    TAKEHARA, T
    HAGIWARA, H
    MITA, E
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    HEPATOLOGY, 1994, 20 (04) : A157 - A157
  • [50] Pegylated interferon alpha2b plus ribavirin in non responder and naive chronic hepatitis C patients.
    Ripault, MP
    Martinot, M
    Boyer, N
    Giuily, N
    Castelnau, C
    Pouteau, M
    Tarik, A
    Marcellin, P
    HEPATOLOGY, 2002, 36 (04) : 596A - 596A